Jacob D. Bitran, M.D., M.B.A., F.A.C.P
- Lymphoma
- Multiple myeloma
- High-risk leukemias
- Stem cell transplantation
Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
- Referring Physicians Phone
(847) 450-0192
- Referring Physicians Fax
(847) 342-4089
- Referring Physicians Email
A nationally renowned expert with more than 50 years of experience treating hematologic malignancies, Jacob D. Bitran, M.D., M.B.A., F.A.C.P., is a clinical professor of hematology and hematopoietic stem cell transplantation at City of Hope® Cancer Center Chicago.
In his practice, Dr. Bitran helps diagnose and treat a wide range of blood cancers, including high-grade lymphoma, high-risk leukemias and myeloma. His goal is to offer curative therapy wherever possible and, if a cure is not possible, to serve patients with compassion and expertise, with the goal of extending their quality of life and their time with their families. His goals are to grow City of Hope Chicago’s stem cell transplant program and to explore leading-edge therapies for conditions such as multiple sclerosis.
As a researcher and scholar, Dr. Bitran has published hundreds of papers, abstracts and book chapters that explore innovative new approaches to hematology-oncology, among many other topics. He has received numerous awards for his work as a physician, educator and clinician, including frequent inclusion on the “Best Doctors in America” list, and is a member of multiple professional associations, including the American Society of Hematology, the International Society of Experimental Hematology, and the American Society of Bone Marrow and Blood Transplantation, and as a diplomate of the American Board of Internal Medicine.
Before taking on his current role at City of Hope, Dr. Bitran led a number of transformative blood cancer and stem cell transplant programs in the Chicagoland area, including those at the University of Chicago and Lutheran General Hospital, where he was also president of the medical staff. Dr. Bitran earned his medical degree at the University of Illinois College of Medicine and completed his internship and residency at Michael Reese Hospital, followed by another residency in pathology at Rush Medical Center and a fellowship in hematology-oncology at the University of Chicago.
Location
Chicago Cancer Center
Zion, IL 60099
North Shore
Morton Grove, IL 60053
Education & Experience
Board Certifications
- Internal Medicine, Medical Oncology and Hematology – American Board of Internal Medicine
Degrees
- University of Illinois College of Medicine, Chicago, IL
- Master of Business Administration – National Louis University, Chicago, IL
Residencies
- Pathology – Rush Medical Center, Chicago, IL
- Internal Medicine – Michael Reese Hospital, Chicago, IL
Fellowship
- Hematology-Oncology – University of Chicago, Chicago, IL
Awards & Memberships
Awards
- 2007 – ongoing “Best Doctors in America”
- 2005 “Top Doctors”
- 2003 “Best Doctors in America”
- 1999 “American Men and Women of Science”
- 1997 – ongoing “Who’s Who in America”
- 1996 “Who’s Who in Science and Engineering”
- 1995 “Who's Who in Science and Technology”
- 1995 “Dictionary of International Biography”
- 1994 “The International Who's Who of Intellectuals”
- 1994 “Best Doctors in America”
- 1994 “American Men and Women of Science”1994 “The International Directory of Distinguished Leadership”
- 1992 “Best Doctors in America”
Memberships
- American Society of Hematology
- American Association for Cancer Research
- American Society of Clinical Oncology
- Chicago Society of Internal Medicine
- American Federation for Clinical Research
- American College of Chest Physicians
- Central Society for Clinical Research
- International Society of Experimental Hematology
- Fellow, American College of Chest PhysiciansInternal Society for Hematotherapy and Graft Engineering
- American Society of Bone Marrow and Blood Transplantation
- European Society for Medical Oncology
Publications
- Bitran J, Daniely D, Forouzan E, et al. A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen. Experimental Hematology. 2022;111:79-86.
- Bitran J, Malas A, Bufalino S, Hancock C. Idiopathic Erythrocytosis: Vascular Complications. Blood. 2021;138(1):4146.
- Bitran J, Knouse P, Pandravada S. Primary Central Nervous System Lymphoma With Systemic Recurrence. Cureus. 2021; 13(9):e18406.
- Bitran J, Gill N, Chandran A, Adley B. Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients. Cureus. 2020; 12(12):e11957.
- Bitran J, Knouse P, Nabrinsky E, et al. DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience. Cureus. 2020;12(11): e11714.
- Hancock C, Knouse P, Almanaseer I, Bitran J. A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged >70 Years): Overall Outcomes. J. Clin. Onco 2018;18(4):280-285.
- Vidisheva AP, Wang J, Spektor TM, Bitran J, et al. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Support Care Cancer. 2017;24(10):3217-3224.
- Coleman M, Kolibaba KS, Brooks HD, Bitran JD, et al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL Analysis of patients with double—refractory or early relapsed follicular lymphoma (FL). J Clin. Oncol. 2017;36(15).
- Berenson R, Cohen A, Spektor TM, Bitran JD, et al. Replacement of ixazomib for relapsed/refractory multiple myeloma patients’ refractory to a bortezomib or carfilzomib-containing combination therapy. J Clin. Oncol. 2017;35(15).
- Li J, Rizvi S, Bitran J, et al. MAGNIFY: Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone, or mantle cell lymphoma. Blood. 2016;128(22):1798.